Skip to main content

Affymetrix Posts 11-Percent Rise in Q2 Profit; Reiterates Q3 Closing for ParAllele Acquisition

NEW YORK, July 21 (GenomeWeb News) - Affymetrix today reported a 5 percent year-over-year increase in revenues and an 11 percent increase in net income for the second quarter of 2005.

 

Total revenue rose to $84.1 million from $79.8 million in the second quarter of 2004. Of the company's total revenues, $1.9 million was attributed to the sale of products to Perlegen Sciences in the current quarter, compared to $1.4 million in sales to Perlegen in the year-ago period.

 

Affymetrix reported an increase in net income to $7.8 million, or $.12 per diluted share, from $7.0 million, or $.11 per diluted share, in the prior-year period.

 

The company did not meet analyst earnings estimates of $.17 per share for the quarter, however.

 

Affymetrix increased quarterly R&D spending to $20.8 million from $17.8 million in the second quarter of 2004.

 

The company had cash and cash equivalents of $27 million on hand as of June 30.

 

Affymetrix reiterated its plans to close its acquisition of ParAllele in the third quarter. As a result, the company expects to incur merger-related charges for in-process R&D of $15 million and operational charges of $7 million in the third quarter.

 

For the third quarter, Affymetrix has forecast total revenue of $95 million and a net loss per share of $.06 - below analyst estimates of net income of net income of $.29 per share.

 

Affymetrix reiterated its previous guidance of $405 million in total revenues for the full year.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.